Molecular Minimal Residual Disease in Acute Myeloid Leukemia

被引:554
|
作者
Jongen-Lavrencic, M. [1 ]
Grob, T. [1 ]
Hanekamp, D. [3 ]
Kavelaars, F. G. [1 ]
al Hinai, A. [1 ]
Zeilemaker, A. [1 ]
Erpelinck-Verschueren, C. A. J. [1 ]
Gradowska, P. L. [2 ]
Meijer, R. [2 ]
Cloos, J. [3 ]
Biemond, B. J. [4 ]
Graux, C. [6 ]
Kooy, M. van Marwijk [5 ]
Manz, M. G. [8 ]
Pabst, T. [9 ]
Passweg, J. R. [10 ]
Havelange, V. [7 ]
Ossenkoppele, G. J. [3 ]
Sanders, M. A. [1 ]
Schuurhuis, G. J. [3 ]
Lowenberg, B. [1 ]
Valk, P. J. M. [1 ]
机构
[1] Erasmus Univ, Med Ctr, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands
[2] Erasmus Univ, Med Ctr, Erasmus MC Canc Inst, HOVON Data Ctr,Dept Hematol, Rotterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands
[4] Acad Med Ctr, Dept Hematol, Amsterdam, Netherlands
[5] Isala Hosp, Zwolle, Netherlands
[6] UCL Namur Godinne, Yvoir, Belgium
[7] Clin Univ St Luc, Dept Hematol, Brussels, Belgium
[8] Univ Zurich Hosp, Dept Hematol, Zurich, Switzerland
[9] Univ Hosp, Bern, Switzerland
[10] Univ Hosp Basel, Div Hematol, Basel, Switzerland
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 378卷 / 13期
关键词
CLONAL HEMATOPOIESIS; MUTATIONS; DNMT3A; REMISSION; PERSISTENCE; YOUNGER; ADULTS; READY; AML;
D O I
10.1056/NEJMoa1716863
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Patients with acute myeloid leukemia (AML) often reach complete remission, but relapse rates remain high. Next-generation sequencing enables the detection of molecular minimal residual disease in virtually every patient, but its clinical value for the prediction of relapse has yet to be established. METHODS We conducted a study involving patients 18 to 65 years of age who had newly diagnosed AML. Targeted next-generation sequencing was carried out at diagnosis and after induction therapy (during complete remission). End points were 4-year rates of relapse, relapse-free survival, and overall survival. RESULTS At least one mutation was detected in 430 out of 482 patients (89.2%). Mutations persisted in 51.4% of those patients during complete remission and were present at various allele frequencies (range, 0.02 to 47%). The detection of persistent DTA mutations (i.e., mutations in DNMT3A, TET2, and ASXL1), which are often present in persons with age-related clonal hematopoiesis, was not correlated with an increased relapse rate. After the exclusion of persistent DTA mutations, the detection of molecular minimal residual disease was associated with a significantly higher relapse rate than no detection (55.4% vs. 31.9%; hazard ratio, 2.14; P<0.001), as well as with lower rates of relapse-free survival (36.6% vs. 58.1%; hazard ratio for relapse or death, 1.92; P<0.001) and overall survival (41.9% vs. 66.1%; hazard ratio for death, 2.06; P<0.001). Multivariate analysis confirmed that the persistence of non-DTA mutations during complete remission conferred significant independent prognostic value with respect to the rates of relapse (hazard ratio, 1.89; P<0.001), relapse-free survival (hazard ratio for relapse or death, 1.64; P = 0.001), and overall survival (hazard ratio for death, 1.64; P = 0.003). A comparison of sequencing with flow cytometry for the detection of residual disease showed that sequencing had significant additive prognostic value. CONCLUSIONS Among patients with AML, the detection of molecular minimal residual disease during complete remission had significant independent prognostic value with respect to relapse and survival rates, but the detection of persistent mutations that are associated with clonal hematopoiesis did not have such prognostic value within a 4-year time frame. (Funded by the Queen Wilhelmina Fund Foundation of the Dutch Cancer Society and others.)
引用
收藏
页码:1189 / 1199
页数:11
相关论文
共 50 条
  • [1] Molecular Minimal Residual Disease in Acute Myeloid Leukemia
    Mauvieux, Laurent
    Miguet, Laurent
    Fornecker, Luc
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25): : 2442 - +
  • [2] Molecular Minimal Residual Disease in Acute Myeloid Leukemia REPLY
    Lowenberg, Bob
    Valk, Peter J. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25): : 2443 - 2443
  • [3] Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
    Vonk, Christian M.
    Al Hinai, Adil S. A.
    Hanekamp, Diana
    Valk, Peter J. M.
    [J]. CANCERS, 2021, 13 (21)
  • [4] Acute myeloid Leukemia: Molecular minimal Residual Disease and Prognosis
    Braess, Jan
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2018, 143 (13) : 930 - +
  • [5] Minimal Residual Disease in Acute Myeloid Leukemia
    Gomez-Arteaga, Alexandra
    Guzman, Monica L.
    [J]. BIOLOGICAL MECHANISMS OF MINIMAL RESIDUAL DISEASE AND SYSTEMIC CANCER, 2018, 1100 : 111 - 125
  • [6] Minimal Residual Disease in Acute Myeloid Leukemia
    Jeyakumar, Deepa
    O'Brien, Susan
    [J]. JAMA ONCOLOGY, 2020, 6 (12) : 1899 - 1900
  • [7] Minimal Residual Disease in Acute Myeloid Leukemia
    Sung, Pamela J.
    Luger, Selina M.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (01)
  • [8] Minimal Residual Disease in Acute Myeloid Leukemia
    Pamela J. Sung
    Selina M. Luger
    [J]. Current Treatment Options in Oncology, 2017, 18
  • [9] Minimal Residual Disease Quantitation in Acute Myeloid Leukemia
    Shook, David
    Coustan-Smith, Elaine
    Ribeiro, Raul C.
    Rubnitz, Jeffrey E.
    Campana, Dario
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S281 - S285
  • [10] MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA PATIENTS
    Van der Velden, Vincent
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2009, 76B (06) : 416 - 416